



(51) International Patent Classification:

C07C 233/75 (2006.01) **C07D 237/24** (2006.01)
C07C 235/56 (2006.01) **A61K 31/235** (2006.01)
C07C 237/42 (2006.01) **A61K 31/192** (2006.01)
C07D 213/30 (2006.01) **A61K 31/166** (2006.01)
C07D 213/80 (2006.01) **A61K 31/44** (2006.01)
C07D 213/81 (2006.01) **A61P 25/28** (2006.01)

(21) International Application Number:

PCT/GB2010/001650

(22) International Filing Date:

1 September 2010 (01.09.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0915196.0 1 September 2009 (01.09.2009) GB

(71) Applicant (for all designated States except US): **KING'S COLLEGE LONDON** [GB/GB]; Strand, London WC2R 2LS (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CORCORAN, Jonathan Patrick Thomas** [GB/GB]; Wolfson Centre for Age-Related Diseases, Wolfson Wing, Hodgkin Building, King's College, London, London SE1 1UL (GB). **KALINDJIAN, Sarkis Barret** [GB/GB]; Wolfson Centre for Age-Related Diseases, Wolfson Wing, Hodgkin Building, King's College, London, London SE1 1UL (GB). **BORTHWICK, Alan David** [GB/GB]; 15 Temple Grove, London NW11 7UA (GB). **ADAMS, David Reginald** [GB/GB]; 32 The Spinney, High Wycombe, Bucks HP11 1QE (GB). **BROWN, Jane Theresa** [GB/GB]; Sygnature Chemical Services, Biocity, Pennyfoot Street, Nottingham NG1 1GF (GB). **TADDEI, David Michel**

Adrien [FR/GB]; Sygnature Chemical Services, Biocity, Pennyfoot Street, Nottingham NG1 1GF (GB). **SHIERS, Jason, John** [GB/GB]; Sygnature Chemical Services, Biocity, Pennyfoot Street, Nottingham NG1 1GF (GB).

(74) Agent: **WILHELMUS, Wytenburg, J.**; Mewburn Ellis LLP, 33 Gutter Lane, London EC2V 8AS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: THERAPEUTIC ARYL-AM I DO-ARYL COMPOUNDS AND THEIR USE



(I)

(57) Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as "AAA compounds"), which, inter alia, are (selective) retinoic acid receptor α (RAR α) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RAR α , and in the treatment of diseases and conditions that are mediated by RAR α , that are ameliorated by the activation of RAR α , etc., including cognitive disorders, memory impairment, memory deficit, senile dementia, Alzheimer's disease, early stage Alzheimer's disease, intermediate stage Alzheimer's disease, late stage Alzheimer's disease, cognitive impairment, and mild cognitive impairment.

